| Description |
Recombinant Biotinylated Human HLA-A*02:01&B2M&MAGE-A2 (KMVELVHFL) Monomer Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus.It contains Gly25-Thr305(HLA-A*02:01), Ile21-Met119(B2M) and KMVELVHFL peptide. |
| Purity |
> 95% as determined by Tris-Bis PAGE;> 95% as determined by HPLC |
| Accession |
A0A140T913(HLA-A*02:01)&P61769(B2M)&KMVELVHFL |
| Target Symbol |
HLA-A*02:01&B2M&MAGE-A2 (KMVELVHFL) Monomer |
| Species |
Human |
| Expression System |
HEK293 |
| Tag |
C-His-Avi |
| Expression Range |
Gly25-Thr305(HLA-A*02:01), Ile21-Met119(B2M) and KMVELVHFL peptide |
| Mol. Weight |
The protein has a predicted MW of 50.50 kDa. Due to glycosylation, the protein migrates to 52-62 kDa based on Tris-Bis PAGE result. |
| Form |
Lyophilized |
| Formulation |
Lyophilized from 0.22 um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
| Endotoxin |
Less than 1EU per ug by the LAL method. |
| Storage |
Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
| Shipping |
Shipped at ambient temperature. |
| Gene Background |
Melanoma antigen gene (MAGE)-A2 (MAGEA2) is a member of the MAGE-A family proteins widely studied for cancer vaccine development and identification of tumor markers. MAGEA2 plays an oncogenic role in glioma progression, and they provide insight into MAGEA2 application as a novel predictor of clinical outcomes and a potential glioma biomarker. |
